In this large and well-established area, the company’s products stand out as innovative and cutting edge with exceptional performance. They are used in academic research laboratories, biopharmaceutical companies, and many more areas. Amidst the pandemic, the company announced the appointment of Jonathan Royce as the new Chief Executive Officer (CEO). Royce has a background in senior leadership roles within large-scale suppliers to the biopharmaceutical market including MerckMillipore and GE Healthcare Life Sciences (now Cytiva). BioSpectrum interacted with Jonathan Royce to find out what Bio-Works has in store for the Indian market. Edited excerpts;
What were the highlights at Bio-Works in 2020?
2020 was a year in which Bio-Works expanded its global reach in several key markets. We established a US-subsidiary and hired two sales managers in the US market (one in Boston, one in San Diego) and substantially grew our business in key Asian markets, most notably South Korea. We brought on Dr. Ravi Rayanade in India as a Director Regional Sales to better be able to serve our growing base of customers in the Indian biotech market. And we added new distributors in India (Arihant and BioLinx) and Taiwan (Yong Chien Technology). Also during the past year, Bio-Works continued its quality improvements with a successful re-certification against the ISO 9001:2015 quality standard. This certification ensures that Bio-Works resins meet the strict requirements of users, who are producing biopharmaceuticals under Good Manufacturing Practices (GMP). We also concluded a number of studies designed to strengthen the data offered to users in our Regulatory Support Files.
What are the major plans for 2021?
This story is from the March 2021 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 2021 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.
